Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call

CRL 10.16.2024

Full Press ReleaseSEC FilingsOur CRL Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
  • 01.16.2025 - Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform
  • 01.14.2025 - Charles River Laboratories at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.14.2025 - 8-K Current report
  • 11.12.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.08.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors

WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 16, 2024--Charles River Laboratories International, Inc.(NYSE: CRL) will release third-quarter 2024 financial results onWednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information onWednesday, November 6th, at9:30 a.m. ET.

Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website atir.criver.com. A replay will be accessible through the same website.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visitwww.criver.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241016333453/en/

Investor Relations Contact:Todd SpencerCorporate Vice President, Investor Relations781.222.6455todd.spencer@crl.com

Source:Charles River Laboratories International, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com